Multiple myeloma - haematology - SA Health Approved Cancer Chemotherapy Protocol Register

Multiple myeloma

Multiple myeloma
Protocol Administration at chemotherapy unit level Review Date
AL amyloidosis melphalan and dexamethasone oral Medium Cycle 1. Low Cycle 2 onwards if patient tolerates March 2022
Multiple myeloma and AL amyloidosis CTD (CYCLOPHOSPHamide thalidomide dexamethasone) oral Low February 2023
Multiple myeloma carfilzomib and dexamethasone twice weekly High cycle 1, Medium cycle 2 onwards if patient tolerates February 2024
Multiple myeloma carfilzomib and dexamethasone weekly High cycle 1, Medium cycle 2 onwards if patient tolerates February 2024
Multiple myeloma CyBorD (CYCLOPHOSPHamide bortezomib dexamethasone) twice weekly Low August 2023
Multiple myeloma CyBorD (CYCLOPHOSPHamide bortezomib dexamethasone) weekly Low August 2023
Multiple myeloma daratumumab High cycle 1, Medium cycle 2 onwards if patient tolerates August 2024
Multiple myeloma daratumumab maintenance High cycle 1, Medium cycle 2 onwards if patient tolerates August 2023
Multiple Myeloma daratumumab SUBCUT 
- SAHCDC Approved non-eviQ protocol Multiple Myeloma daratumumab SUBCUT (PDF 2.3MB)
Low,
Confirm nursing/pharmacy manufacturing availability for Regional LHN sites
December 2024
Multiple Myeloma daratumumab SUBCUT bortezomib dexamethasone 
- SAHCDC Approved non-eviQ protocol Multiple Myeloma daratumumab SUBCUT bortezomib dexamethasone (PDF 3.3MB)
Low,
Confirm nursing/pharmacy manufacturing availability for Regional LHN sites
December 2024
Multiple myeloma DRd (daratumumab lenalidomide dexamethasone) High cycle 1, Medium cycle 2 onwards if patient tolerates August 2023
Multiple myeloma DT-PACE (dexamethasone thalidomide cISplatin DOXOrubicin CYCLOPHOSPHamide etoposide) High August 2024
Multiple myeloma DVd (daratumumab bortezomib dexamethasone) treatment overview 
The SAHCDC has endorsed the use of weekly dosing of Bortezomib (Day 1, 8 and 15) for patients unable/unlikely to tolerate twice weekly dosing
High cycle 1, Medium cycle 2 onwards if patient tolerates August 2023
Multiple myeloma D-VMP (daratumumab bortezomib melphalan prednisolone) High cycle 1, Medium cycle 2 onwards if patient tolerates August 2023
Multiple Myeloma elotuzumab lenalidomide dexamethasone  interim Multiple Myeloma elotuzumab lenalidomide dexamethasone protocol (PDF 431KB)
Medium December 2023
Multiple myeloma ixazomib lenalidomide and dexamethasone oral Low February 2024
Multiple myeloma lenalidomide and dexamethasone oral Low February 2024
Multiple myeloma lenalidomide maintenance post autologous transplant Low August 2023
Multiple myeloma MPB (melphalan prednisolone bortezomib) Medium cycle 1, Low cycle 2 on if patient tolerates August 2024
Multiple myeloma MPT (melphalan prednisolone thalidomide) oral Low August 2023
Multiple myeloma pomalidomide and dexamethasone oral 
The SAHCDC has endorsed the use of weekly dosing of Bortezomib (Day 1, 8 and 15) for patients unable/unlikely to tolerate twice weekly dosing
Low February 2023
Multiple myeloma PVd (pomalidomide bortezomib and dexamethasone)3 Low August 2023
Multiple myeloma RVd (lenalidomide bortezomib dexamethasone) PETHEMA overview Low February 2023
Multiple myeloma induction RVd (lenalidomide bortezomib dexamethasone) PETHEMA Low February 2023
Multiple myeloma consolidation RVd (lenalidomide bortezomib dexamethasone) PETHEMA Low February 2023
Multiple myeloma RVd (lenalidomide bortezomib dexamethasone) SWOG S0777 overview Low February 2023
Multiple myeloma induction RVd (lenalidomide bortezomib dexamethasone) SWOG S0777 Low February 2023
Multiple myeloma RVd-lite (lenalidomide bortezomib dexamethasone) overview Low February 2023
Multiple myeloma induction RVd-lite (lenalidomide bortezomib dexamethasone) Low February 2023
Multiple myeloma consolidation RVd-lite lenalidomide and bortezomib Low February 2023
Multiple myeloma maintenance RVd-lite lenalidomide Low February 2023
Multiple myeloma thalidomide and dexamethasone oral Low February 2023

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.